Vermillion to Present at B. Riley & Co. 13th Annual Investor Conference on May 23, 2012
AUSTIN, Texas, May 9, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has been invited to present at the B. Riley & Co. 13th Annual Investor Conference. The conference will be held at the Loews Santa Monica Beach Hotel in Santa Monica, California on May 21-23, 2012.
Vermillion President and CEO Gail S. Page is scheduled to present on Wednesday, May 23, 2012 at 11:00 a.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company's business plan and objectives for 2012.
OVA1®, the company's flagship product, recently received a Category 1 Current Procedural Terminology (CPT®) code approval from the American Medical Association (AMA), which is a critical step to overall market adoption of a new diagnostic test.
For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your B. Riley & Co. representative.
About B. Riley & Co.
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K, as amended, and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.
SOURCE Vermillion, Inc.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here